GLAXOSMITHKLINE CEO SAYS NOT SURE A SINGLE NARRATIVEAROUND SECTOR M&AGLAXOSMITHKLINE CEO SAYS NO UPDATE ON CHINAINVESTIGATIONGLAXOSMITHKLINE CEO SAYS U.S. ADVAIR SHARE FELL IN EARLYJANUARY BUT HAS SINCE STABILISEDGLAXOSMITHKLINE CEO SAYS UK HAS "TERRIFIC" SCIENCE BASEAND GREAT SUPPORT FOR INVESTMENT VIA PATENT BOXGLAXOSMITHKLINE CEO, ASKED ABOUT PFIZER, SAYS HOPESRATIONAL PEOPLE WILL CHOOSE TO INVEST IN UKGLAXOSMITHKLINE CEO DECLINES TO COMMENT ON POTENTIALINTEREST IN ASTRAZENECA BUT SAYS WON'T BE DISTRACTED FROM ITSCORE R&D BUSINESSGLAXOSMITHKLINE CEO SAYS MAY DISPOSE OF INDIVIDUALESTABLISHED DRUGS OR BROADER PORTFOLIO OF PRODUCTSGLAXOSMITHKLINE CEO SAYS PREFERS TO DO VERY TARGETEDTRANSACTIONSGLAXOSMITHKLINE CEO SAYS TARGETED DEALS DIFFICULT,SOMETIMES THE TRADITIONAL APPROACH TO M&A IS EASIERGLAXOSMITHKLINE CEO SAYS BROAD-SCALE TRANSACTIONS"DISTRACTING"
TOP NEWS: GSK's bepirovirsen receives US FDA fast track designation
(Alliance News) - GSK PLC on Monday said that the US health watchdog granted fast track designation for its bepirovirsen treatment for chronic hepatitis B.
Read more